Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Melanoma|Non-small Sell Lung Cancer (NSCLC)|Triple Negative Breast Cancer|Anaplastic Thyroid Cancer|Other Solid Tumors
Interventions: BIOLOGICAL: PDR001
Sponsor: Novartis Pharmaceuticals